化合物VPS34 T7944

Product Introduction
Bioactivity


英文名: VPS34 inhibitor 1 (Compound 19, PIK-III analogue)

描述: VPS34 inhibitor 1 (Compound 19, PIK-III analogue) (PIK-III analogue) 是一种有效的选择性 VPS34抑制剂( IC50 : 15 nM)。

细胞实验: Cell lines: U2OS cells.Concentrations: 0, 1, 5, 10 μM. Incubation Time: 24 h .Method: For inhibitor assay, cells are plated and the following day when cells had reached 90%, are treated with dimethyl sulfoxide (DMSO, vehicle) or the indicated concentration of PIK-III or Compound 19, both dissolved in DMSO. 24 hours later, cells are lysed in RIPA supplemented with 1% SDS and mini-EDTA protease inhibitors, homogenized by passage through a Qiashredder column and the protein is quantified by DC Lowry protein assay.

动物实验: Animal Models: C57BL/6 Mice. Formulation: PG (20% v/v). Dosages: 10 mg/kg(p.o.) or 2 mg/kg(I.V.) .Administration: oral administration or I.V.

体外活性: VPS34 inhibitor 1 (Compound 19, PIK-III analogue) is extraordinarily selective over other lipid and protein kinases. The ability of compound 19 to prevent the degradation of autophagy substrates p62, NCOA4, NBR1, NDP52, and FTH1 is similar to PIK-III. In addition, treatment of cells with compound 19 leads to an increase in the lipidated and nonlipidated forms of LC3 similar to previous reports using PIK-III.

体内活性: The pharmacokinetic profile of analogue 19 is determined in C57BL/6 mice.?After oral administration at 10 mg/kg, the compound is rapidly absorbed and showed moderate mean systemic clearance (30 mL/min/kg, approximately 33% of hepatic blood flow), with good oral bioavailability (F% = 47).?Based on these PK parameters and the cellular activity, compound 19 constitutes a suitable candidate for in vivo studies.?Upon oral administration of compound 19 at 50 mg/kg twice a day (BID) for 7 days, LC3-II accumulates consistent with reduced autophagic capacity in time-dependent manner.?It inhibits autophagy in vivo.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 78 mg/mL (199.25 mM)


关键字: inhibit | VPS34 | oral | VPS-34 inhibitor 1 (Compound 19, PIK-III analogue) | Inhibitor | VPS34 inhibitor 1 (Compound 19, PIK III analogue) | lysosomal | Compound 19, PIK-III analogue | degradation | Phosphoinositide 3-kinase | PI3K | selective | VPS34 inhibitor 1 (Compound 19, PIKIII analogue) | Autophagy | VPS34 inhibitor 1

相关产品: Hirsutenone | Vistusertib | IHMT-PI3Kδ-372 S-isomer | Sonolisib | Ginsenoside Rk1 | Leniolisib | NU 7026 | GDC-0349 | 1,3-Dicaffeoylquinic acid | Serabelisib

相关库: Antioxidant Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Cancer Metabolism Compound Library | Anti-Lung Cancer Compound Library | Kinase Inhibitor Library | Inhibitor Library | Highly Selective Inhibitor Library | Metabolism Compound Library | Glycolysis Compound Library | Bioactive Compound Library

化合物VPS34 T7944信息由TargetMol中国为您提供，如您想了解更多关于化合物VPS34 T7944报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途